Abcellera Biologics Inc (ABCL) — Capital Reinvestment Ratio
Abcellera Biologics Inc (ABCL) has a Capital Reinvestment Ratio of 1.38x as of June 2023, meaning it reinvests 1% of its operating cash flow ($19.82 Million) in capital expenditures ($27.35 Million). See Abcellera Biologics Inc (ABCL) balance sheet quality index to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Abcellera Biologics Inc Capital Reinvestment Ratio (2018–2022)
This chart tracks Abcellera Biologics Inc's Capital Reinvestment Ratio across 5 annual periods. Check Abcellera Biologics Inc investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Abcellera Biologics Inc (2018–2022)
Year-by-year Capital Reinvestment Ratio for Abcellera Biologics Inc from 2018 to 2022. For live market cap and broader valuation context, see market cap of Abcellera Biologics Inc.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2022 | 0.26x | $277.36 Million | $72.66 Million | ▲ +9.6% |
| 2021 | 0.24x | $244.58 Million | $58.45 Million | ▼ -63.0% |
| 2020 | 0.65x | $22.69 Million | $14.67 Million | ▼ -56.4% |
| 2019 | 1.48x | $2.69 Million | $4.00 Million | ▼ -0.3% |
| 2018 | 1.49x | $3.56 Million | $5.31 Million | — |